GetTopicDetailResponse(id=fe861549eae, topicName=ripretinib, introduction=ripretinib, content=null, image=null, comments=5, allHits=900, url=https://h5.medsci.cn/topic?id=15497, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=95512, tagList=[TagDto(tagId=95512, tagName=ripretinib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1577068, encodeId=76be15e7068b8, content=<a href='/topic/show?id=fe861549eae' target=_blank style='color:#2F92EE;'>#ripretinib#</a>, objectTitle=Lancet oncol：III期試驗：ripretinib單藥治療晚期胃腸間質腫瘤的療效和安全性, objectType=article, longId=195474, objectId=2d9e1954e445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d9e1954e445, replyNumber=0, likeNumber=99, createdTime=2020-06-09, rootId=0, userName=12498568m55暫無昵稱, userId=c69216379233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d9e1954e445, moduleTitle=Lancet oncol：III期試驗：ripretinib單藥治療晚期胃腸間質腫瘤的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2d9e1954e445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577067, encodeId=ac9b15e706745, content=<a href='/topic/show?id=fe861549eae' target=_blank style='color:#2F92EE;'>#ripretinib#</a>, objectTitle=FDA批準Ripretinib用于四線晚期胃腸道間質瘤治療！再鼎醫(yī)藥持有中國權益, objectType=article, longId=194393, objectId=2d8619439350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d8619439350, replyNumber=0, likeNumber=80, createdTime=2020-05-20, rootId=0, userName=12498568m55暫無昵稱, userId=c69216379233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d8619439350, moduleTitle=FDA批準Ripretinib用于四線晚期胃腸道間質瘤治療！再鼎醫(yī)藥持有中國權益, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2d8619439350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577066, encodeId=5c7a15e706602, content=<a href='/topic/show?id=fe861549eae' target=_blank style='color:#2F92EE;'>#ripretinib#</a>, objectTitle=晚期胃腸道間質瘤（GIST）患者的新希望！四線療法Ripretinib獲FDA批準, objectType=article, longId=194259, objectId=741619425993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=741619425993, replyNumber=0, likeNumber=73, createdTime=2020-05-18, rootId=0, userName=12498568m55暫無昵稱, userId=c69216379233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=741619425993, moduleTitle=晚期胃腸道間質瘤（GIST）患者的新希望！四線療法Ripretinib獲FDA批準, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=741619425993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577065, encodeId=eff015e706589, content=<a href='/topic/show?id=fe861549eae' target=_blank style='color:#2F92EE;'>#ripretinib#</a>, objectTitle=Ripretinib治療晚期胃腸道間質瘤取得NDA優(yōu)先審查權, objectType=article, longId=188009, objectId=684e1880092a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=684e1880092a, replyNumber=0, likeNumber=73, createdTime=2020-02-15, rootId=0, userName=12498568m55暫無昵稱, userId=c69216379233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=684e1880092a, moduleTitle=Ripretinib治療晚期胃腸道間質瘤取得NDA優(yōu)先審查權, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=684e1880092a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577064, encodeId=f54915e7064de, content=<a href='/topic/show?id=fe861549eae' target=_blank style='color:#2F92EE;'>#ripretinib#</a>, objectTitle=2019 ESMO|ripretinib或可成為經重度治療的GIST患者的標準治療, objectType=article, longId=181107, objectId=b30018110e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b30018110e10, replyNumber=0, likeNumber=135, createdTime=2019-10-15, rootId=0, userName=12498568m55暫無昵稱, userId=c69216379233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b30018110e10, moduleTitle=2019 ESMO|ripretinib或可成為經重度治療的GIST患者的標準治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b30018110e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
